Zicthoru (diclofenac sodium) / Hisamitsu - LARVOL DELTA

Z&A Therapy: Pain Alleviation and Appetite Stimulation in Pancreatic Cancer Patients Using ZICTHORU® Tapes and Anamorelin (ASA 2025) - "Based on these observations, we tentatively refer to this combined approach as Z&A Therapy, a strategy that warrants further investigation for its potential role in enhancing patient outcomes. Notably, despite the use of NSAIDs, eGFR improved in both cases, suggesting that pain alleviation and subsequent increases in physical activity may have contributed to better renal function."

Clinical • Oncology • Pain • Pancreatic Cancer • Solid Tumor

A Case Report of Pain Control and Renal Function Improvement Using ZICTHORU® Tapes in a Patient with Multiple Myeloma (ASA 2025) - "Although NSAIDs are generally avoided in multiple myeloma due to renal risks, the low systemic exposure of ZICTHORU® may minimize renal burden. This case suggests that controlling pain with novel diclofenac tapes may support renal function recovery by promoting exercise."

Case report • Clinical • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Pain

Stable Analgesia, Reduced Hepatic Burden: Pharmacokinetic and Pharmacodynamic Advantages of Transdermal Diclofenac Tape(ZICTHORU® Tape) in Personalized Oncology Care (ASA 2025) - "Oral NSAIDs such as naproxen and diclofenac undergo significant hepatic metabolism during the first-pass effect, potentially exacerbating existing liver dysfunction, particularly in patients receiving hepatotoxic anticancer therapies such as tyrosine kinase inhibitors and immunotherapy agents...G represents the period, including nighttime, during which the concentration remains above the dashed-line threshold when 225mg ZICTHORU® Tapes is applied once a day. These pharmacokinetic characteristics suggest that ZICTHORU®Tapes provides a more stable and sustained plasma concentration, potentially enhancing pain management while minimizing peak-related side effects."

PK/PD data • Hepatology • Liver Failure • Musculoskeletal Pain • Pain

Effective and Safe Switch from Oral NSAIDs to a Novel Diclofenac Tape (ZICTHORU®️ Tapes) in a Patient With Cabozantinib-induced Liver Injury: Consideration of the First Pass Effect (ASA 2023) - "The palliative care team addressed pain control by changing the patient from Naproxen 300mg three times daily to ZICTHORU®️ Tapes 150mg daily. Following radiotherapy to the spine, the patient's pain and liver dysfunction stabilized (Figure), and he was discharged."

Clinical • Back Pain • Genito-urinary Cancer • Hepatology • Liver Failure • Musculoskeletal Pain • Oncology • Pain • Palliative care • Renal Cell Carcinoma • Solid Tumor

Hisamitsu / FY19 financial results domestic prescription drug business down 3.4% revenue forecast for FY20 is ‘undecided’ with new corona [Google translation] (Mix Online) - "We expect to obtain approval for two projects in Japan in FY2020...The other is the cancer pain of HP-3150 (development code, generic name: diclofenac sodium), a transdermal non-steroidal pain treatment drug. Approval will be obtained....Originally we were planning to apply in FY20, but in February of 2020 we applied for approval ahead of schedule....In clinical trials, efficacy was evaluated by administration once daily."

Japanese regulatory • Back Pain • CNS Disorders • Musculoskeletal Pain • Pain